Agilent Technologies Inc. announced the release of a new range of high performance liquid chromatography (HPLC) columns ideally suited for biotherapeutics applications. The Agilent Altura Ultra Inert HPLC Columns set a new standard in liquid chromatography performance, providing the reliability and efficiency biopharmaceutical companies need for the most demanding applications, including peptide GLP-1 and oligonucleotide therapeutic development and quality control.
The rapidly evolving biopharma market faces unique challenges in the pursuit of innovative biotherapeutics. High-performance columns and lower limits of detection are required for biopharma labs to accelerate the discovery of these peptide- and oligonucleotide-based therapeutics and meet increasingly rigorous regulatory expectations.
Altura HPLC columns unlock the full separation potential of the stationary phase, delivering superior chromatographic performance—faster conditioning, improved peak shape, and enhanced sensitivity—for even the most challenging analytes. Agilent’s in-house expertise in inert coating, exemplified by the proprietary Ultra Inert technology featured in Altura HPLC columns, delivers consistent, robust performance under demanding operating conditions. This innovation is central to Agilent’s long-term strategy for LC column development.
The Altura line of LC columns further expands Agilent’s broad range of solutions supporting a fully inert sample flow path. A key addition to their inert flow path portfolio, this launch reinforces Agilent’s focus on delivering innovative products to drive the development and production of exceptionally high-quality therapeutics.